Mankind Pharma Ltd Q2FY26 – ₹3,697 Cr Sales, ₹520 Cr Profit, and ₹797 Cr Shopping Spree!India’s Favourite Pill Merchant Flexes Harder Than Your Gym Trainer
1. At a Glance
Ladies and gentlemen, presenting Mankind Pharma Limited (NSE: MANKIND, BSE: 543904) — the company that sells everything from pregnancy kits to heart pills, and somehow keeps Amitabh Bachchan, Ranveer Singh, and Sunny Leone on the same payroll. As of November 6, 2025, the stock closed at ₹2,309, giving it a market cap of ₹95,316 crore — a pharmaceutical kingdom ruled by the Juneja clan.
This quarter (Q2FY26) was full of both pills and thrills: sales rose 20.8% YoY to ₹3,697 crore, while PAT stood at ₹520 crore (down 22% YoY, because taxes and acquisitions don’t come cheap). Operating margins held firm at 25%, proving that while profits dipped, efficiency didn’t lose its chill.
With a P/E of 54.5x, ROCE of 16%, and ROE of 14.7%, Mankind’s valuation is somewhere between a well-branded unicorn and a blue-chip pharma darling. Debt climbed to ₹8,369 crore (post Bharat Serums acquisition), but with zero promoter pledges, the Junejas seem confident this pill will go down smoothly.
Think of it as India’s “Desi Pfizer” — with condoms, cough syrups, cardiac drugs, and chronic cash flow, all under one highly medicated umbrella.
2. Introduction
Once upon a prescription pad, two brothers from Delhi — Ramesh and Rajeev Juneja — decided that India needed more affordable medicines and more glamorous advertisements. Fast-forward three decades, and Mankind Pharma has evolved from a backroom generics player to a full-blown pharma + FMCG hybrid empire.
You’ve probably met Mankind already — not at the stock exchange, but at your local chemist or late-night grocery store. “Unwanted-72”? That’s them. “Prega News”? Yep, them again. “Manforce”? Of course — the brand that’s saved more awkward pharmacy conversations than any other.
While most pharma companies obsess over molecules, Mankind obsesses over market share. With #1 ranking in prescriptions and #4 position in Indian Pharma Market (IPM) by value, this company has perfected the science of mixing business with Bollywood.
But here’s the twist: beneath the glittering ad campaigns lies a serious pharmaceutical machine. Mankind commands leadership in Gynaecology, Dermatology, and Anti-infectives, while rapidly expanding in chronic therapies like Cardiovascular and Diabetes.
The result? A company that’s as much a marketing powerhouse as a medical marvel — equal parts chemist and comedian, with product launches that trend faster than Koffee with Karan episodes.
3. Business Model – WTF Do They Even Do?
If India’s healthcare system had a “Bigg Boss,” Mankind would be that one contestant who plays every game, flirts with every segment, and still walks away with the trophy.
Mankind Pharma develops, manufactures, and markets pharmaceutical formulations across acute and chronic therapeutic areas, plus a rapidly growing consumer healthcare division.
Consumer Healthcare: The “BollyPharma” side — Manforce Condoms, Prega News, Gas-O-Fast, AcneStar, HealthOK, Unwanted-72.
The revenue mix for Q3FY25 was dominated by Anti-infectives (14%), Cardiovascular (15%), Gastro (9%), Gynaecology (9%), Anti-diabetic (8%), and Consumer Health (7%).
In short — if it’s inside your body, on your body, or about to be inside someone else’s body, Mankind probably has a product for it.
4. Financials Overview
Metric
Latest Qtr (Q2FY26)
YoY Qtr (Q2FY25)
Prev Qtr (Q1FY26)
YoY %
QoQ %
Revenue (₹ Cr)
3,697
3,061
3,570
+20.8%
+3.6%
EBITDA (₹ Cr)
924
847
847
+9.1%
0.0%
PAT (₹ Cr)
520
659
445
-21.1%
+16.9%
EPS (₹)
12.4
16.3
10.6
-23.9%
+16.9%
Annualized EPS = ₹12.4 × 4 = ₹49.6 At ₹2,309/share, P/E = 46.5x (educational value, not recommendation).
🩺 Commentary: Mankind’s numbers show a company flexing its top-line muscles while nursing a profit hangover from heavy investments and acquisitions. Revenue growth looks strong, but margin compression hints that integration and tax bills hit the bottom line.
5. Valuation Discussion – Fair Value Range (Educational Purpose Only)
Let’s brew three valuation cocktails — shaken, not stirred:
(a) P/E Method:
Annualized EPS: ₹49.6
Reasonable P/E range (industry): 30x–50x
Fair Value Range: ₹1,488 – ₹2,480 per share
(b) EV/EBITDA Method:
EV = ₹1,03,125 Cr; EBITDA (TTM) = ₹3,267 Cr
EV/EBITDA = 31.6x (Current) Assume sector comfort range 20x–25x → Implied EV = ₹65,000 – ₹81,675 Cr → Equity Value ~₹57,000 – ₹73,000 Cr → Fair Value Range: ₹1,400 –
